icenticaftor icenticaftor icenticaftor (development code qbw251) is a drug candidate for the treatment of chronic obstructive pulmonary disease (copd) and cystic fibrosis. the drug is being developed by novartis. icenticaftorclinical dataother namesqbw251atc codenoneidentifiers iupac name 3-amino-6-methoxy-n--5-(trifluoromethyl)pyridine-2-carboxamide cas number1334546-77-8pubchem cid58442344chemspider88296259uniiamb0bo0wfhkeggd12454chemical and physical dataformulac12h13f6n3o3molar mass361.244 g·mol−13d model (jsmol)interactive image smiles c(cnc(=o)c1=c(c=c(c(=n1)oc)c(f)(f)f)n)(c(f)(f)f)o inchi inchi=1s/c12h13f6n3o3/c1-10(23,12(16,17)18)4-20-8(22)7-6(19)3-5(11(13,14)15)9(21-7)24-2/h3,23h,4,19h2,1-2h3,(h,20,22)/t10-/m0/s1key:ushqrikzlhnpqr-jtqlqieisa-n like ivacaftor (which is marketed as kalydeco), icenticaftor functions by acting as a stimulator of the protein cystic fibrosis transmembrane conductance regulator (cftr).